Dasatinib

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

CAS number 302962-49-8

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Tyrosine kinase inhibitor for the treatment of oncological diseases ( orphan drug).

Pharmacodynamics (Effect)This section has been translated automatically.

The translocation between chromosomes 9 and 22 is characteristic of chronic myeloid leukemia (CML) (Philadelphia chromosome). This leads to the oncogene known as BCR-ABL.

This oncogene is a cytoplasmic tyrosine kinase that phosphorylates various substrates. BCR-ABL inhibits normal cell proliferation and differentiation.

Imatinib inhibits the BCR-ABL tyrosine kinase activity. It specifically blocks the binding site for ATP at the tyrosine kinase BCR-ABL. This inhibits the transfer of ATP phosphate groups to tyrosine residues of the substrates.

In this way, signal transduction within cells is prevented. Thus, processes of migration, invasion angiogenesis, proliferation and anti-apoptosis are disturbed.

IndicationThis section has been translated automatically.

Orphan drug designation for chronic myeloid leukemia, primary eosinophilia when other therapies including imatinib are not tolerated and acute lymphoblastic leukemia (ALL) in Philadelphia chromosome-positive adults (Ph+).

Pregnancy/nursing periodThis section has been translated automatically.

Teratogenicity was described in animal experiments. Do not use during pregnancy or lactation!

Dosage and method of useThis section has been translated automatically.

Depending on the indication: 1 time a day 100-140 mg p.o. (in the morning).

Undesirable effectsThis section has been translated automatically.

Nausea, vomiting, diarrhoea, myalgia, muscle cramps, erythema, increase in transaminases, edema.

ContraindicationThis section has been translated automatically.

Hypersensitivity to the active substance or any of the other ingredients.

PreparationsThis section has been translated automatically.

Sprycel

LiteratureThis section has been translated automatically.

  1. Gabrielli A et al (2007) Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmune Rev 7: 121-126
  2. Gabrielli A et al (2007) Pathogenic autoantibodies in systemic sclerosis. Curr Opin Immunol 19: 640-645
  3. Goldman JM et al (2003) Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 349: 1451-1464
  4. Kähler HC et al. (2009) Skin changes caused by "targeted therapies" in oncological patients. Dermatologist 60: 433-440
  5. Svegliati S et al (2007) Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110: 237-241

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer